tbuckley/cabot-search huggingface dataset:
The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,
Authors: Junya Kanda, David A. Rizzieri, Gwynn D. Long, Cristina Gasparetto, John P. Chute, Keith M. Sullivan, Ashley Morris, Jacalyn McPherson, J. Andrew Livingston, Gloria Broadwater, Donna Niedzwiecki, Nelson J. Chao, Mitchell E. Horwitz
Journal: Blood (2011)
Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients
Authors: Cinzia Pellegrini, Alessandro Broccoli, Beatrice Casadei, Annalisa Chiappella, Paolo Corradini, Enrico Derenzini, Anna Dodero, Lucia Farina, Letizia Gandolfi, Marco Ladetto, Federico Monaco, Lorella Orsucci, Federica Quirini, Flavia Salvi, Francesco Spina, Vittorio Stefoni, Lorenzo Tonialini, Umberto Vitolo, Lisa Argnani, Pier Luigi Zinzani
Journal: Blood (2015)
A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.
Authors: Miguel Ortin, Sue Bricknell, Sheila Gribben, Lynn Stirrup, Martin Dyer, Ann Hunter
Journal: Blood (2005)
Role of Previous Thalidomide Administration on Final Outcome for 72 Patients with Relapsed Multiple Myeloma (MM) Treated with Bortezomib–Based Therapy
Authors: Massimo Offidani, Laura Corvatta, Claudia Polloni, Maria-Novella Piersantelli, Silvia Gentili, Miriana Ruggieri, Lara Malerba, Francesco Alesiani, Massimo Catarini, Marino Brunori, Arduino Samori, Maurizio Burattini, Luisa Minnucci, Anna Mele, Monica Marconi, Pietro Leoni
Journal: Blood (2008)
Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
Authors: D Barraco, S Cerquozzi, C A Hanson, R P Ketterling, A Pardanani, N Gangat, A Tefferi
Journal: Blood Cancer Journal (2017)

In 2012, the International Working Group for Myeloproliferative Neoplasms (MPN) Research and Treatment (IWG-MRT) reported an associations between mild bone marrow (BM) fibrosis (⩾grade 1) in polycythemia vera (PV) and a lower incidence of thrombosis during the clinical course and a higher risk of fibrotic progression. The objective in the current study of 262 patients with PV was to validate these observations and also identify other risk factors for myelofibrosis-free survival (MFFS). About 127 (48%) patients displayed ⩾grade 1 reticulin fibrosis at the time of diagnosis; presenting clinical and laboratory features were not significantly different between patients with or without BM fibrosis. In univariate analysis, BM fibrosis had no significant impact on overall, leukemia-free or thrombosis-free survival, whereas a significant association was noted for MFFS (P=0.009, hazard ratio 2.9; 95% confidence interval 1.32-6.78); other risk factors for MFFS included leukocytosis ⩾15 × 109/l, presence of palpable splenomegaly and abnormal karyotype. During multivariable analysis, leukocytosis ⩾15 × 109/l, palpable splenomegaly and ⩾grade 1 BM reticulin fibrosis remained significant. The current study validates the previously observed association between ⩾grade 1 BM reticulin fibrosis in PV and subsequent fibrotic progression, and identifies leukocytosis and palpable splenomegaly as additional risk factors for fibrotic progression; additional studies are required to clarify the impact of BM fibrosis on thrombosis and that of abnormal karyotype on MFFS.
Haloperidol-Associated Uterine Dystonia
Authors: Kathryn K. Ridout, Samuel J. Ridout
Journal: American Journal of Psychiatry (2017)

TO THE EDITOR: Haloperidol is a first-generation antipsychotic recommended for psychosis in pregnancy (1).Up to 60% of patients on first-generation antipsychotics develop an acute dystonia (2).Haloperidol could induce uterine or fetal dystonia (3), although this has not been previously reported.We report the case of a pregnant 27-year-old woman who experienced uterine dystonia associated with haloperidol:
Human Plasmacytoid Dendritic Cell like Leukemia Cell Line (PMDC05) Established from a Patient with CD4+CD56+ Acute Leukemia.
Authors: Miwako Narita, Nozomi Tochiki, Norihiro Watanabe, Anri Saitoh, Shigeo Hashimoto, Junjiro Tsuchiyama, Tatsuo Furukawa, Sadao Aoki, Ichiro Fuse, Yoshifusa Aizawa, Masuhiro Takahashi
Journal: Blood (2006)
Abstract P2-07-06: Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients
Authors: O Aseyev, C Johnson, M Turek, E Stadnick, A Law, N Gosh, S Dent
Journal: Cancer Research (2017)

Abstract Background. Clinical trials have demonstrated an increased risk of cancer treatment related cardiac dysfunction (CTCD) during trastuzumab(H) therapy. Diabetes, dyslipidemia, and obesity are also known risk factors for cardiovascular disease. The primary objective of this study was to evaluate the incidence of asymptomatic drop in left ventricular ejection fraction (AD-LVEF) and symptomatic CTCD (S-CTCD) in women with BC and co-morbidities receiving H, referred to a dedicated cardio-oncology clinic (COC). Methods. This was a retrospective cohort study of women with BC (all stages) referred to The Ottawa Hospital COC between 2008 and 2015, who received chemotherapy (CT) and H. Data collected included: demographics, reason for referral, cardiac testing (MUGA/ECHO) co-morbidities (diabetes, dyslipidemia) and cardiac outcomes. Obesity defined as body mass index &amp;gt; 30. Symptomatic CTCD include SOB, PND, orthopnea, peripheral edema, congestive heart failure. Asymptomatic drop in LVEF defined as decrease of at least 15% from baseline; normal LVEF, or a decrease of at least 10% in LVEF, less than 53%. Results. Chemotherapy (A-CT) followed by H, 62 received H without A-CT. 139 patients with no history diabetes, dyslipidemia, or obesity, referred with AD-LVEF (68%), with S- CTCD (30%), pre-CT assessment (2%). Obesity (O) pre-existing co-morbidity in 63 (26%) patients, (20 (32%) with S-CTCD, 40 (63%) referred with AD-LVEF, 3(5%) referred for pre-CT assessment). Dyslipidemia (L) – 52 (21%); referred with S-CTCD 15; 29%), with AD-LVEF 31 (60%), pre-CT assessment 6 (11). Diabetes (D) – 29 (12%) - (6 (21%) with S-CTCD, 19 (66%) referred with AD-LVEF, 4(13%) referred for pre-CT assessment). Combination of two or three conditions significantly increase incidence of S-CTCD: O+L – 67%, O+D – 69%, O+L+D – 72%. Combination of obesity and other conditions significantly increase incidence of S-CTCD: O+L – 67%(Relative Risk -2.2, p=0,04), O+D – 69% (RR-2.3, p=0,02), O+L+D – 72% (RR-2.4, p=0,08). Conclusion. The combination of two or three co-morbidities significantly increases the incidence of S-CTCD. BC patients experiencing CTCD with pre-existing history of diabetes, dyslipidemia, and obesity may require more proactive strategies for prevention, detection and treatment of cardiotoxicity during trastuzumab-based treatment. Citation Format: Aseyev O, Johnson C, Turek M, Stadnick E, Law A, Gosh N, Dent S. Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-07-06.
Repairing of Homing Defect in Cord Blood Hematopoietic Stem Cell Transplantation–Comparison of Fucosyltransferase VII with Fucosyltransferase VI.
Authors: Wan Xiang, Hiromasa Miyaji, Hidetaka Sato, Len Miller, Sun Zimin, Lijun Xia
Journal: Blood (2012)
A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
Authors: Yoo-Joung Ko, Vincent Channing Tam, Nicole Mittmann, Mark Pasteka, Kelvin K. Chan
Journal: Journal of Clinical Oncology (2013)

e17569 Background: FOLFIRINOX has been shown to be superior to gemcitabine (gem) alone for metastatic pancreatic cancer (MPC) and has been established as the standard of care. A recent study (von Hoff et al, GI ASCO 2013) showed that gem + nab-paclitaxel (gem+nab-p) was superior to gem alone. The cost-effectiveness of gem+nab-p relative to gem or FOLFIRINOX has not been studied. Methods: A Markov cohort model was constructed for patients with MPC to examine the costs and outcomes of gem alone, gem+nab-p and FOLFIRINOX. Efficacy and side-effect data were obtained from pivotal phase III trials. Resource utilization data, unit costs and utilities were obtained from Ontario Ministry of Health and Long-Term Care, Sunnybrook Health Sciences Centre and the literature. The primary outcome was the incremental cost-effectiveness ratio (ICER) defined as cost per quality-adjusted life year (QALY). The analysis was conducted from the perspective of the Canadian public healthcare system over a 2-year time horizon adjusted to 2012 Canadian dollars (CAD$). Both cost and effectiveness were discounted at 5%. One way and probabilistic sensitivity analyses were performed. Results: Using gem as the base case, gem+nab-p had better outcomes but higher costs (see Table). The ICER was higher than conventional willingness-to-pay (WTP) threshold. Gem+nab-p was less effective but less costly when compared with FOLFIRINOX. It was dominated by combinations of gem and FOLFIRINOX (i.e. extended dominance), and therefore not cost-effective regardless of WTP threshold. If the price of nab-p was 20% lower, then gem+nab-p and FOLFORINOX would have similar cost-effectiveness. Conclusions: Gem+nab-p is not cost-effective, from the Canadian perspective, for the treatment of MPC based on the current price when compared with FOLFIRINOX. A lower-priced generic oxaliplatin, which is available in some jurisdictions including the United States, may affect the outcome of this analysis in further favor of FOLFIRINOX. [Table: see text]
Active Combination Therapy of Bortezomib (Velcade) and Ibritumomab Tiuxetan (Zevalin) in an In Vivo Diffuse Large B-Cell Lymphoma Model.
Authors: Milena Pervan, Jeffrey Calimlim, Dan Matso, Jonathan W. Said, William H. McBride, Sven de Vos
Journal: Blood (2005)
Hepatogastric fistula as a rare complication of pyogenic liver abscess
Authors: Kyu Won Lee, Hee Yeon Kim, Chang Wook Kim, Young Ki Kim, Ohbeom Kwon, Min Ah Kim, Youngyun Cho, Keungmo Yang
Journal: Clinical and Molecular Hepatology (2017)

Hepatogastric fistula following a pyogenic liver abscess is extremely rare, and only a handful of cases have been reported. An 88-year-old female presented with generalized weakness, fever and chills. An abdominal computed tomography scan revealed a 5cm-sized hypodense lesion with internal septa in the left lateral section of the liver. Due to initial suspicion of early liver abscess, she was treated with empirical intravenous antibiotics. Initially, aspiration or drainage of the liver abscess was not performed due to immature lesion characteristics. An ultrasonography-guided percutaneous drainage of the liver abscess was performed 17 days after hospitalization due to a more mature lesion appearance on follow-up imaging. On tubography, contrast media leakage through the fistulous tract was visualized. Surgical management was performed, and she was discharged 2 weeks after surgery.
Idiotypic Vaccination of Patients with Relapsed Follicular Lymphoma Using a Novel Vaccine Formulation Including a Tobacco Plant-Produced Tumor Specific Idiotype
Authors: Maurizio Bendandi, Carlos Becerra, Joseph Kuhn, Suncica Hukic, Nyla Langford, Taizoon Khokhar, Victor Klimyuk, Yuri Gleba, Romy Kandzia, Frank Thieme, Franziska Jarczowski, Jens Uwe Kuenstler, Madhuri Vusirikala, Nora Ku, Robert H. Collins
Journal: Blood (2011)
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Authors: Gerard Sanacora, Mark A. Frye, William McDonald, Sanjay J. Mathew, Mason S. Turner, Alan F. Schatzberg, Paul Summergrad, Charles B. Nemeroff
Journal: JAMA Psychiatry (2017)

<h3>Importance</h3> Several studies now provide evidence of ketamine hydrochloride’s ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. <h3>Observations</h3> This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option. <h3>Conclusions and Relevance</h3> The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.
Abstract P4-20-04: Young women with breast cancer in Mexico: A report of the pilot phase of the “Mujer Joven y Fuerte” prospective cohort
Authors: CM Villareal-Garza, A Platas, A Castro-Sánchez, M Miaja, E Bargalló-Rocha, BA Martinez-Cannon, Y Vega, A Fonseca, P Ramos-Elias, CJ Márquez-Perez, A Bukowski, P Goss, J St. Louis, J-A Chapman, A Partridge, A Meneses, A Mohar
Journal: Cancer Research (2017)

Abstract Background: Despite high rates of breast cancer in young women from low-and-middle-income countries (LMICs), their needs and concerns are not systematically studied or addressed. Understanding the characteristics of young women with breast cancer (YWBC) and the issues they face is of great relevance to the medical community, in order to tailor clinical interventions and supportive care for this unique and understudied patient population. The Mexican cohort “Mujer Joven y Fuerte” (Young and Strong Woman) has the goal of comprehensively characterizing and assessing the needs of YWBC in Mexico using patient- and physician-based surveys. Methods: A prospective cohort of newly diagnosed YWBC was established in November 2014 at two Mexican cancer centers in Mexico City and Monterrey. Eligible women answer web-based surveys on relevant topics including physical activity, genetics, psychosocial needs, and fertility. Clinicians complete pre-specified surveys using the US NIH BOLD Task Force common data elements registering clinical/pathologic characteristics and outcomes. Patients are evaluated at diagnosis, after 6 months, and annually for 5 years. Sub-studies assessing changes in cognition, sexual function and satisfaction, quality of life and depression/anxiety are being conducted, and biologic samples are stored for future research. Results: 96 YWBC with median age at diagnosis of 34 (21-41 y) were accrued to our pilot phase. 26% were single and 25% childless. 43% had higher education and 28% were employed. 90% presented with a self-detected mass. Clinical stage at diagnosis was distributed as follows: stage 0: 2%; I: 15%; IIA: 13%; IIB: 17%; III: 47%, and stage IV: 6%. The most frequent molecular subtype was HR+/HER2- (47%), followed by HER2+ (26%) and triple negative (21%). First follow-up results will be available shortly. Conclusions: To our knowledge, this represents the first prospective cohort of YWBC in Latin America. We are expanding this project to other centers in the region. Our findings will help develop culturally tailored interventions aimed at improving the psychosocial and medical outcomes of this vulnerable patient population. Citation Format: Villareal-Garza CM, Platas A, Castro-Sánchez A, Miaja M, Bargalló-Rocha E, Martinez-Cannon BA, Vega Y, Fonseca A, Ramos-Elias P, Márquez-Perez CJ, Bukowski A, Goss P, St. Louis J, Chapman J-A, Partridge A, Meneses A, Mohar A. Young women with breast cancer in Mexico: A report of the pilot phase of the “Mujer Joven y Fuerte” prospective cohort [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-20-04.
Whole exome sequencing coupled with unbiased functional analysis reveals new Hirschsprung disease genes
Authors: Hongsheng Gui, Duco Schriemer, William W. Cheng, Rajendra K. Chauhan, Guillermo Antiňolo, Courtney Berrios, Marta Bleda, Alice S. Brooks, Rutger W. W. Brouwer, Alan J. Burns, Stacey S. Cherny, Joaquin Dopazo, Bart J. L. Eggen, Paola Griseri, Binta Jalloh, Thuy-Linh Le, Vincent C. H. Lui, Berta Luzón-Toro, Ivana Matera, Elly S. W. Ngan, Anna Pelet, Macarena Ruiz-Ferrer, Pak C. Sham, Iain T. Shepherd, Man-Ting So, Yunia Sribudiani, Clara S. M. Tang, Mirjam C. G. N. van den Hout, Herma C. van der Linde, Tjakko J. van Ham, Wilfred F. J. van IJcken, Joke B. G. M. Verheij, Jeanne Amiel, Salud Borrego, Isabella Ceccherini, Aravinda Chakravarti, Stanislas Lyonnet, Paul K. H. Tam, Maria-Mercè Garcia-Barceló, Robert M. W. Hofstra
Journal: Genome biology (2017)

Hirschsprung disease (HSCR), which is congenital obstruction of the bowel, results from a failure of enteric nervous system (ENS) progenitors to migrate, proliferate, differentiate, or survive within the distal intestine. Previous studies that have searched for genes underlying HSCR have focused on ENS-related pathways and genes not fitting the current knowledge have thus often been ignored. We identify and validate novel HSCR genes using whole exome sequencing (WES), burden tests, in silico prediction, unbiased in vivo analyses of the mutated genes in zebrafish, and expression analyses in zebrafish, mouse, and human.We performed de novo mutation (DNM) screening on 24 HSCR trios. We identify 28 DNMs in 21 different genes. Eight of the DNMs we identified occur in RET, the main HSCR gene, and the remaining 20 DNMs reside in genes not reported in the ENS. Knockdown of all 12 genes with missense or loss-of-function DNMs showed that the orthologs of four genes (DENND3, NCLN, NUP98, and TBATA) are indispensable for ENS development in zebrafish, and these results were confirmed by CRISPR knockout. These genes are also expressed in human and mouse gut and/or ENS progenitors. Importantly, the encoded proteins are linked to neuronal processes shared by the central nervous system and the ENS.Our data open new fields of investigation into HSCR pathology and provide novel insights into the development of the ENS. Moreover, the study demonstrates that functional analyses of genes carrying DNMs are warranted to delineate the full genetic architecture of rare complex diseases.
Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).
Authors: Sergio Giralt, Rupi Thandi, Muzaffar Qazilbash, Floralyn Mendoza, Eric Han, Chitra Hosing, Michael Wang, Sheeba Thomas, Raymond Alexanian, Richard Champlin, Donna Weber
Journal: Blood (2007)
Impact of Dose Reductions and Interruptions Due to Adverse Events (AEs) on Efficacy in Newly Diagnosed Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Patients (pts) Receiving Either Dasatinib (D) or Imatinib(IM): Analysis of the DASISION Trial
Authors: Elias Jabbour, Hagop M Kantarjian, Alfonso Quintas-Cardama, Francois Guilhot, Chao Zhu, Janet Hong, Zachary Cain, Jorge E. Cortes
Journal: Blood (2011)
Republican plan to repeal Obamacare draws fire from left and right
Authors: Michael McCarthy
Journal: BMJ (2017)

After vowing to repeal the Barack Obama’s Affordable Care Act since its passage in 2010, Republicans in the House of Representatives Monday 6 March submitted a long awaited replacement bill1 that has a chance of passage, now that the Republicans have gained control of both chambers of Congress and the presidency.

“It’s time to turn a page and rescue our healthcare system from this disastrous law,” said House speaker Paul Ryan, a Republican from Wisconsin, who said that the new plan would “drive down costs, encourage competition, and give every American access to quality, affordable health insurance.”

But the bill was immediately denounced by Democrats, who said that it would increase the number of people without insurance, and by conservatives, including members of the Republican party, who said that it still allows too much government intrusion into the US healthcare system.

Since the passage of the 2010 law, often called Obamacare, Republicans in Congress have voted more than 50 times to repeal or …
Different Stress Responses Mediate the Massive Erythroblast Expansion Occurring in Cultures of Human Progenitor Cells Derived From Cord Blood and Adult Blood in the Presence of Glucocorticoid Receptor Agonists.
Authors: Giulia Federici, Valentina Tirelli, Francesca Masiello, Lilian Varricchio, Gabriella Girelli, Ann Zeuner, Emanuel F. Petricoin, Anna Rita F Migliaccio
Journal: Blood (2012)
Abstract P5-16-27: Variation in the use of neoadjuvant chemotherapy for breast cancer in the Netherlands. A lack of consensus
Authors: PER Spronk, ACM Bommel van, S Siesling, M-JT Vrancken Peeters, CM Smorenburg
Journal: Cancer Research (2017)

Abstract Introduction Neoadjuvant chemotherapy (NAC) is an important initial strategy in the management of stage III locally advanced breast cancer (LABC) as being advised in our national guidelines. Furthermore, NAC is increasingly being used in stage II BC for downsizing the tumour in order to enable breast conservation therapy (BST). The aim of this study was to examine which patient-, tumour- and hospital related factors influence its use in clinical daily practice. In addition, we investigated the preferences of the surgical- and medical- oncologist as well as the patients'. Methods (1) All operated women [aged 18-70] from January 2011 to September 2015 were selected from the multidisciplinary NABON Breast Cancer Audit (NBCA). Multivariable logistic regression was used to assess significant independent predictors of NAC use. (2) Both specialists and ex-patients were provided with a survey about decision-making. Results Overall, 21% of stage II (N=18011) and 70% of stage III patients (N=1715) received NAC. Factors associated with NAC utilization included young age, a diagnostic MRI, histology, large tumour size, more advanced nodal disease, hormone-receptor negative tumours and participation in neoadjuvant trials.After case mix correction variation between hospitals remained (range 10% – 90%). Evidenced by additional survey research, reasons for indication of NAC vary widely among specialists (response rate of 24%; N=100). From the patient survey (response rate of 52%; N=390) it appears that in patients where chemotherapy is recommended, 50% was not informed about the option of NAC. Conclusion There is considerable variation in the use of NAC for BC in the Netherlands. Although various patient, tumor and institutional factors are associated with the use of NAC, these can only explain part of the observed variation in treatment patterns between hospitals. Survey research shows a need for uniformity of selection criteria in the use of NAC between specialists. Also, the information necessary for patients to decide on which treatment option they prefer seems far from complete in clinical practice. Citation Format: Spronk PER, Bommel van ACM, Siesling S, Vrancken Peeters M-JT, Smorenburg CM. Variation in the use of neoadjuvant chemotherapy for breast cancer in the Netherlands. A lack of consensus [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-27.
Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.
Authors: Asher Alban Chanan-Khan, Sundar Jagannath, Robert L. Schlossman, Robert J. Fram, Richard M. Falzone, Mary F. Ruberti, Samantha K. Welch, Dawn DePaolo, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2006)